11.1 C
New York
Sunday, November 24, 2024
HomeUK NewsLabour Party pledges to regulate UK pharmaceutical market

Labour Party pledges to regulate UK pharmaceutical market

Date:

Related stories

Manhunt underway for husband after murder of Harshitha Brella in east London

Police are searching for Pankaj Lamba, who is suspected...

London mayor Sadiq Khan criticizes Trump’s policies as divisive and prejudiced

London Mayor Sadiq Khan has condemned U.S. president-elect Donald...

Starmer attends Armistice Day in Paris, first UK PM to participate since Churchill

In a historic move, Prime Minister Keir Starmer attended...

Badenoch appoints Priti Patel and Mel Stride to lead Tory shadow cabinet

Opening Paragraph: Conservative Party leader Kemi Badenoch has appointed Mel...

Reeves to prioritize NHS with significant funding boost in budget

Chancellor Rachel Reeves is set to announce billions of...

Britain’s opposition Labour Party leader Jeremy Corbyn pledged on Tuesday to reform the pharmaceutical market to force drug companies to produce generic versions of new medicines and give the state a greater role in research and production.

Corbyn announced the policy in his address to Labour’s annual conference, part of a wave of planned reforms the party hopes will help them win an early election, which is expected to be called in the coming months.

“We will redesign the system to serve public health – not private wealth – using compulsory licensing to secure generic versions of patented medicines,” Corbyn said in his speech

“We’ll tell the drugs companies that if they want public research funding then they’ll have to make their drugs affordable for all,” he added.

Labour would also create a new publicly owned generic drugs manufacturer to supply cheaper medicines to the National Health Service, he said.

- Advertisement -

A separate Labour briefing document said the party expected its reforms to be opposed by the industry, and acknowledged the changes were complex and risky.

But it said the potential savings from the shift away from the current monopolistic model of research and development outweighed any associated costs, and that an overall R&D spending increase would dissuade manufacturers from pulling out of the UK market.

“Making the case for an expanded role of the state does not negate the participation of the private sector, but rather redefines its role,” the document said.

“By changing the incentives to innovate, by setting conditions on public investment and increasing the role of the public sector in overseeing the production of medicines, we can maximise the public value of private-sector contributions.”

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

LEAVE A REPLY

Please enter your comment!
Please enter your name here